Formulation Development and in vitroCharacterizations of Captopril TripleLayer Matrix Tablets

Abstract

Background: Captopril, an antihypertensive agent, has a relatively short elimination half-life (2 h). Thus, there
is a strong clinical need and market potential for a dosage form that will deliver Captopril in a sustained manner.
Objective: The objective of the present work was to formulation development and in vitro characterizations
of Captopril triple layer matrix tablets using Sodium alginate for optimum drug release of Captopril to achieve
sustain drug release to reach proper serum concentration in a specific period of time for sustained therapeutic
action. Results: 200 mg of Sodium alginate granules containing 70% (S1), 80% (S2) of Sodium alginate on either
sides of Captopril matrix granules (200 mg) containing either 30% (C1), 40% (C2) of Sodium alginate. The values
of percent friability of multi-layered tablets were in the range of 0.24 ± 0.04–30.32 ± 0.07%. The hardness and
friability test prove good binding of granules as wet granulation method was used. The drug content was well
within the range of contained 98.32 ± 0.05–99.55 ± 0.06, indicating uniform mixing of Sodium alginate, drug, and
other formulation excipient. The percentage in vitro drug release of formulations was ranges from 91.75 ± 0.16
to 99.76 ± 0.36. Conclusion: Formulation development and in vitro characterizations of Captopril triple-layer
matrix tablets using Sodium alginate for optimum drug release of Captopril is done.